Study of the role of VEGF-A and VEGF-A165b in pathophysiology of pulmonary hypertensio
Not Applicable
- Conditions
- pulmonary artery hypertension
- Registration Number
- JPRN-UMIN000032723
- Lead Sponsor
- agoya Universiy
- Brief Summary
sVEGF-A165b has the potential to detect LD-PH among the etiologies of PH, and sES may detect CTD-PAH in PAH. In addition, sES may be a marker to estimate the severity of PH. Because sES was correlated with the main items of the ESC risk table, sES is thought to reflect the severity of PH in recent treatment strategies. Further studies are needed in a treatment-naive cohort to verify the usefulness of sES.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Diagnosis of malignant tumor Those already using pulmonary vasodilator (prostaglandin I 2 preparation, endothelin receptor antagonist, phosphodiesterase 5 inhibitor, stimulant of soluble guanylate cyclase)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method